Eli Lilly and Company Common St (NYSE:LLY):
Lilly to Present Latest Data for TaltzÂ® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress.
In the market the company is trading up by 1.43 percent from yesterday’s close.
Additionally Eli Lilly and Company Common St declared a dividend for shareholders paid on Friday the 9th of September 2016. The dividend was $0.510 per share for the quarter or $2.04 annualized. The dividend yield was $2.51. The ex-dividend date was Thursday the 11th of August 2016.
The stock last traded at $80.70 slightly over $79.31, the stock’s 50 day moving average and a bit higher than the 200 day moving average of $76.97. The 50 day moving average moved up $1.17 whereas the 200 day moving average was up $3.51 or +4.56%.
Eli Lilly and Company Common St currently has a P/E ratio of 34.69 and the market value is 85.12B. As of the last earnings report the EPS was $2.32 and is projected to be $3.59 for the current year with 1,057,699,000 shares now outstanding. Next quarter’s EPS is forecasted at $0.95 and the next full year EPS is anticipated to be $4.09.
Several brokerage firms have released opinions on Eli Lilly and Company Common St recently. On September 8 the company was upgraded to “Overweight” from “Neutral” in a report issued by JP Morgan. On May 2 Leerink Swann held the stock rating at “Outperform” but raised the price target from $90.00 to $91.00.
May 1 investment analysts at Credit Suisse maintained a company rating of “Outperform” and lowered the price target to $91.00 from $105.00. On April 6, 2016 Societe Generale released its first research report on the stock with a rating of “Hold”.
On March 15 Jefferies kept the company rating at “Buy” but moved down the price target from $110.00 to $105.00. On December 28 Leerink Partners held the company rating at “Outperform” but raised the price expectation from $93.00 to $95.00.